128 related articles for article (PubMed ID: 3622601)
21. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.
Tzartos SJ
In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis.
Lennon VA; Lambert EH; Leiby KR; Okarma TB; Talib S
J Immunol; 1991 Apr; 146(7):2245-8. PubMed ID: 2005394
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis.
Vernet-der Garabedian B; Morel E; Bach JF
J Neuroimmunol; 1986 Jul; 12(1):65-74. PubMed ID: 3711314
[TBL] [Abstract][Full Text] [Related]
24. Immunological and pharmacological heterogeneity of alpha-bungarotoxin binding sites extracted from TE671 cells.
Walker R; Vincent A; Newsom-Davis J
J Neuroimmunol; 1988 Aug; 19(1-2):149-57. PubMed ID: 3397405
[TBL] [Abstract][Full Text] [Related]
25. A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines.
Keefe D; Hess D; Bosco J; Tzartos S; Powell J; Lamsa J; Josiah S
Cytometry B Clin Cytom; 2009 May; 76(3):206-12. PubMed ID: 18825779
[TBL] [Abstract][Full Text] [Related]
26. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
27. Antimuscle and antiacetylcholine receptor antibodies in myasthenia gravis.
Penn AS; Schotland DL; Lamme S
Muscle Nerve; 1986 Jun; 9(5):407-15. PubMed ID: 3724787
[TBL] [Abstract][Full Text] [Related]
28. Thymopoietin, a thymic polypeptide, regulates nicotinic alpha-bungarotoxin sites in chromaffin cells in culture.
Quik M; Afar R; Geertsen S; Audhya T; Goldstein G; Trifaró JM
Mol Pharmacol; 1990 Jan; 37(1):90-7. PubMed ID: 1967819
[TBL] [Abstract][Full Text] [Related]
29. Myasthenia gravis and myasthenic syndromes.
Engel AG
Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
[TBL] [Abstract][Full Text] [Related]
30. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.
Tindall RS
Ann Neurol; 1981 Nov; 10(5):437-47. PubMed ID: 7305297
[TBL] [Abstract][Full Text] [Related]
31. Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries.
Rey E; Zeidel M; Rhine C; Tami J; Krolick K; Fischbach M; Sanz I
Clin Immunol; 2000 Sep; 96(3):269-79. PubMed ID: 10964546
[TBL] [Abstract][Full Text] [Related]
32. Seronegative myasthenia gravis.
Vincent A; McConville J; Farrugia ME; Newsom-Davis J
Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterization of an acetylcholine receptor-transferrin fusion protein for the treatment of myasthenia gravis.
Keefe D; Parng C; Lundberg D; Ray S; Martineau-Bosco J; Leng C; Tzartos S; Powell J; Concino M; Heartlein M; Lamsa J; Josiah S
Autoimmunity; 2010 Dec; 43(8):628-39. PubMed ID: 20402568
[TBL] [Abstract][Full Text] [Related]
34. Interaction of myasthenic immunoglobulins and cholinergic agonists on acetylcholine receptors of rat myotubes.
Ashizawa T; Elias SB; Appel SH
Ann Neurol; 1982 Jan; 11(1):22-7. PubMed ID: 6277235
[TBL] [Abstract][Full Text] [Related]
35. Anti-acetylcholine receptor antibodies in myasthenia gravis: binding to membrane-bound Torpedo AChR.
Koethe SM; DuPont BL; Calvo AM; Otterson G; McQuillen MP
Ann N Y Acad Sci; 1987; 505():557-65. PubMed ID: 3479936
[No Abstract] [Full Text] [Related]
36. Antibodies to synthetic peptide (125-148) of the alpha-subunit of human nicotinic acetylcholine receptor in sera from patients with myasthenia gravis.
Ohta M; Ohta K; Itoh N; Nishitani H; Hara H; Hayashi K
Neurology; 1990 Nov; 40(11):1776-8. PubMed ID: 2234435
[TBL] [Abstract][Full Text] [Related]
37. Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain.
Whiting PJ; Cooper J; Lindstrom JM
J Neuroimmunol; 1987 Oct; 16(2):205-13. PubMed ID: 3624454
[TBL] [Abstract][Full Text] [Related]
38. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis.
de la Porte S; Ragueh F; Eymard B; Courbin P; Chapron J; Koenig J
J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074
[TBL] [Abstract][Full Text] [Related]
39. Anti-presynaptic membrane receptor antibodies in myasthenia gravis.
Lu CZ; Link H; Mo XA; Xiao BG; Zhang YL; Qin Z
J Neurol Sci; 1991 Mar; 102(1):39-45. PubMed ID: 1856731
[TBL] [Abstract][Full Text] [Related]
40. Future therapeutic strategies in autoimmune myasthenia gravis.
Psaridi-Linardaki L; Mamalaki A; Tzartos SJ
Ann N Y Acad Sci; 2003 Sep; 998():539-48. PubMed ID: 14592926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
